1.42
price up icon0.00%   0.00
after-market After Hours: 1.40 -0.02 -1.41%
loading
Geron Corp stock is traded at $1.42, with a volume of 6.36M. It is up +0.00% in the last 24 hours and down -16.47% over the past month. Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.42
Open:
$1.39
24h Volume:
6.36M
Relative Volume:
0.44
Market Cap:
$859.83M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-4.4375
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+11.81%
1M Performance:
-16.47%
6M Performance:
-65.02%
1Y Performance:
-60.11%
1-Day Range:
Value
$1.36
$1.44
1-Week Range:
Value
$1.27
$1.47
52-Week Range:
Value
$1.17
$5.34

Geron Corp Stock (GERN) Company Profile

Name
Name
Geron Corp
Name
Phone
(650) 473-7700
Name
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Name
Employee
229
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
GERN's Discussions on Twitter

Compare GERN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GERN
Geron Corp
1.42 859.83M 29.48M -201.19M -216.50M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Geron Corp Stock (GERN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-27-25 Downgrade B. Riley Securities Buy → Neutral
Feb-26-25 Downgrade H.C. Wainwright Buy → Neutral
Nov-05-24 Initiated H.C. Wainwright Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Sep-09-24 Initiated Leerink Partners Outperform
Apr-30-24 Downgrade Robert W. Baird Outperform → Neutral
Apr-29-24 Initiated TD Cowen Buy
Mar-15-24 Reiterated Needham Buy
Sep-12-23 Upgrade Goldman Neutral → Buy
Mar-28-23 Initiated Goldman Neutral
Oct-28-22 Initiated Wedbush Outperform
Jul-28-22 Resumed B. Riley Securities Buy
Nov-02-21 Initiated Robert W. Baird Outperform
Feb-18-21 Resumed B. Riley Securities Buy
Aug-03-20 Initiated Stifel Buy
Nov-19-19 Resumed B. Riley FBR Buy
Sep-03-19 Initiated H.C. Wainwright Buy
Aug-15-19 Initiated Cantor Fitzgerald Overweight
Apr-09-19 Upgrade Needham Hold → Buy
Jan-31-19 Upgrade B. Riley FBR Neutral → Buy
Oct-02-18 Downgrade B. Riley FBR Buy → Neutral
Jul-05-18 Initiated B. Riley FBR, Inc. Buy
Sep-13-16 Reiterated FBR & Co. Outperform
Sep-13-16 Reiterated FBR Capital Outperform
Dec-07-15 Reiterated Piper Jaffray Overweight
Apr-21-15 Initiated Oppenheimer Outperform
Jun-12-14 Upgrade MLV & Co Hold → Buy
Mar-12-14 Downgrade MLV & Co Buy → Hold
Dec-10-13 Reiterated MLV & Co Buy
Dec-10-13 Upgrade Needham Hold → Buy
Nov-08-13 Reiterated MLV & Co Buy
Oct-16-13 Initiated MLV & Co Buy
Aug-30-12 Initiated Stifel Nicolaus Buy
Jun-28-12 Initiated Needham Hold
View All

Geron Corp Stock (GERN) Latest News

pulisher
Apr 27, 2025

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 27, 2025
pulisher
Apr 26, 2025

GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - The Victoria Advocate

Apr 26, 2025
pulisher
Apr 25, 2025

Investors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class ActionGERN - PR Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

ROSEN, A LEADING NATIONAL FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN - GlobeNewswire Inc.

Apr 24, 2025
pulisher
Apr 24, 2025

The Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire

Apr 24, 2025
pulisher
Apr 21, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm - TradingView

Apr 21, 2025
pulisher
Apr 21, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - StreetInsider

Apr 21, 2025
pulisher
Apr 20, 2025

2025-04-20 | Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN | NDAQ:GERN | Press Release - Stockhouse

Apr 20, 2025
pulisher
Apr 18, 2025

Geron Expands Team with 12 Strategic Hires, Grants $1.5M+ in Equity Awards Under Nasdaq Rule - Stock Titan

Apr 18, 2025
pulisher
Apr 18, 2025

Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? - Insider Monkey

Apr 18, 2025
pulisher
Apr 18, 2025

Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - StreetInsider

Apr 18, 2025
pulisher
Apr 17, 2025

11 Most Promising Penny Stocks According to Analysts - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Contact The Gross Law Firm by May 12, 2025 Deadline to Join Class Action Against Geron Corporation (GERN) - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Geron Shareholder Sues Executives Over Drug Launch Misrepresentations - USA Herald

Apr 17, 2025
pulisher
Apr 16, 2025

Geron Shareholder Sues Execs Over Drug Launch Claims - Law360

Apr 16, 2025
pulisher
Apr 16, 2025

Geron stock hits 52-week low at $1.19 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Geron Brass Sued Over Cancer Drug Prospects After 32% Stock Drop - Bloomberg Law News

Apr 16, 2025
pulisher
Apr 16, 2025

Geron stock hits 52-week low at $1.19 amid sharp annual decline - Investing.com Canada

Apr 16, 2025
pulisher
Apr 16, 2025

Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

Geron Brass Sued Over Cancer Drug Prospects After Stock Drop (1) - Bloomberg Law News

Apr 16, 2025
pulisher
Apr 15, 2025

13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire

Apr 15, 2025
pulisher
Apr 14, 2025

GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus

Apr 14, 2025
pulisher
Apr 13, 2025

Geron (GERN) to Announce Q1 Financial Results - GuruFocus

Apr 13, 2025
pulisher
Apr 13, 2025

Geron Corporation (GERN) Faces Significant Stock Decline Amidst Volatility - GuruFocus

Apr 13, 2025
pulisher
Apr 13, 2025

2025-04-13 | Shareholders that Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky About Pending Class ActionGERN | NDAQ:GERN | Press Release - Stockhouse

Apr 13, 2025
pulisher
Apr 11, 2025

Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire

Apr 11, 2025
pulisher
Apr 10, 2025

Kirby McInerney LLP Urges Investors in Geron Corporation - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Apr 10, 2025
pulisher
Apr 09, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Geron Corp (GERN) Reports Q3 2023 Financial Results and Business Highlights - GuruFocus

Apr 09, 2025
pulisher
Apr 08, 2025

Geron stock touches 52-week low at $1.27 amid market challenges - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Geron's SWOT analysis: biotech firm's stock faces growth hurdles amid promising drug developments - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Geron’s SWOT analysis: biotech firm’s stock faces growth hurdles amid promising drug developments - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Should You Invest in Geron Corporation (GERN)? - MSN

Apr 08, 2025
pulisher
Apr 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Apr 07, 2025
pulisher
Apr 04, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - PR Newswire

Apr 04, 2025
pulisher
Apr 03, 2025

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Geron - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

GERN INVESTOR DEADLINE: Geron Corporation Investors with Substan - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Victoria Advocate

Apr 03, 2025
pulisher
Apr 03, 2025

GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Apr 03, 2025
pulisher
Apr 02, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Apr 02, 2025
pulisher
Apr 01, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XPLR, Geron, enCore, and Fluence and Encourages Investors to Contact the Firm - GlobeNewswire

Apr 01, 2025

Geron Corp Stock (GERN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):